Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receives the US FDA’s Fast Track Designation for Chronic Kidney Disease

 Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receives the US FDA’s Fast Track Designation for Chronic Kidney Disease

Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receives the US FDA’s Fast Track Designation for Chronic Kidney Disease

Shots:

  • The FDA’s FT designation follows EMPA-KIDNEY study assessing Jardiance (10mg, qd) vs PBO in ~6000 patients with CKD. The study was initiated based on the results of EMPA-REG OUTCOME study which showed the 39% reduction in the risk of new-onset and worsening kidney disease in patients with T2D
  • The ongoing EMPA-KIDNEY study is evaluating the effect of Jardiance on the progression of kidney disease and the occurrence of CV death in adults with established CKD with/without diabetes
  • Jardiance is an oral therapy used to lower the blood sugar level in adults with T2D and CV diseases and is contraindicated in patients with T1D and diabetic ketoacidosis

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly, Boehringer Ingelheim

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post